humanitarian
Archived signal Translated · Українська · 2–5m lag
Звіт про лікування людських ліків (EPAR): Steceyema, ustekinumab, Date of Pritoration: 22/08/2024, module: 10, Status: Authorized
Звіт про лікування людських ліків (EPAR): Zumrad, Sasanlimab, status: application Remote
Reported by EMA What Is New
Read the complete report at EMA What Is New ↗
Verification notice
IntelMap indexes open-source reporting. This page identifies what a source reported; it does not independently confirm the claim.
12 reports · 2 sources
EMA What Is NewЗвіт про лікування людських ліків (EPAR): Steceyema, ustekinumab, Date of Pritoration: 22/08/2024, module: 10, Status: AuthorizedEMA What Is NewЗвіт про лікування людських ліків (EPAR): Steceyema, ustekinumab, Date of Pritoration: 22/08/2024, module: 10, Status: AuthorizedEMA What Is NewHuman medicines European public assessment report (EPAR): Avtozma, tocilizumab, Date of authorisation: 14/02/2025, Revision: 8, Status: AuthorisedEMA What Is NewHuman medicines European public assessment report (EPAR): Avtozma, tocilizumab, Date of authorisation: 14/02/2025, Revision: 8, Status: AuthorisedEMA What Is NewЗвіт про лікування людських ліків (EPAR): Sepalna, snapariv, status: cysEMA What Is NewHuman medicines European public assessment report (EPAR): Ruxolitinib Zentiva, ruxolitinib, Status: OpinionEMA What Is NewHuman medicines European public assessment report (EPAR): Povofortay, povorcitinib, Status: OpinionEMA What Is NewHuman medicines European public assessment report (EPAR): Zeydovio, glepaglutide, Status: OpinionEMA What Is NewHuman medicines European public assessment report (EPAR): Adcomfo, omalizumab, Status: OpinionEMA What Is NewHuman medicines European public assessment report (EPAR): Lifyorli, relacorilant, Status: OpinionEMA What Is NewHuman medicines European public assessment report (EPAR): Inijaq, tofacitinib, Status: OpinionEMA What Is NewHuman medicines European public assessment report (EPAR): Frehemgo, denecimig, Status: Opinion8 recorded states
Signal first indexedP2 · 99% quality · 2 sources
Headline updatedP2 · 99% quality · 2 sources
Source details updatedP2 · 99% quality · 2 sources
Source details updatedP2 · 99% quality · 2 sources
Source details updatedP2 · 99% quality · 2 sources
Source details updatedP2 · 99% quality · 2 sources
Source details updatedP2 · 99% quality · 2 sources
Source details updatedP2 · 99% quality · 2 sources